Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus.

ABSTRACT: Patients with type 2 diabetes mellitus are at risk for accelerated cognitive decline and dementia. Furthermore, their risk of stroke is increased and their outcome after stroke is worse than in those without diabetes. Incretin-based therapies are a class of antidiabetic agents that are of interest in relation to these cerebral complications of diabetes. Two classes of incretin-based therapies are currently available: the glucagon-like-peptide-1 agonists and the dipeptidyl peptidase-4 -inhibitors. Independent of their glucose-lowering effects, incretin-based therapies might also have direct or indirect beneficial effects on the brain. In the present review, we discuss the potential of incretin-based therapies in relation to dementia, in particular Alzheimer's disease, and stroke in patients

SUBMITTER: Groeneveld ON 

PROVIDER: S-EPMC4718099 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature